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Introduction: Cancer induced bone pain (CIBP) is frequent in patients with non-small cell
lung cancer (NSCLC). Radiation therapy continues to be the gold standard for treatment
of painful bone metastases, however only a limited number of metastases can be
irradiated. We evaluated non-radiation based early CIBP relief options in NSCLC
through a systematic review.
Methods: Systematic review including all prospective articles published between 01-1994
and 06-2020 on Pubmed, Cochrane Library and ClinicalTrials.gov database. Inclusion: non-
radiation based trials evaluating CIBP early pain relief options (initially defined as pain score
evaluated within two weeks, because of no randomized trials, later inclusion broadened to
pain score evaluated within six weeks) in ≥10 NSCLC patients. Radioisotope trials were
excluded as these treatments have interactions with systemic anticancer therapy.
Results: 188 articles were found; 10 articles (6 randomized controlled (4 double blinded), 1
phase II single-arm, and 3 prospective trials) fulfilled the inclusion criteria. Six of these trials
consisted of ≥2 treatment arms, whereas the others were single-arm studies. In total, 554
NSCLC patients were evaluated in these trials. The included trials were very heterogeneous
regarding evaluated treatment options, methods of pain measuring, and endpoints. No
high-level evidence for specific early pain relief treatment options was found.
Discussion: Non-radiation based studies evaluating treatment options to rapidly reduce
CIBP in NSCLC are scarce. This systematic review shows that there is no high-level
evidence to recommend a specific treatment for early pain relief. Future research should
focus on early pain relief treatment options for CIBP in NSCLC.
Keywords: non-small cell lung cancer, bone metastases, cancer induced bone pain, pain relief, bisphosphonates,
systematic reviewOctober 2020 | Volume 10 | Article 5092971
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Bone metastases are diagnosed in 24%–70% of patients with
non-small cell lung cancer (NSCLC) during the course of the
disease (1–3). Up to 80% of these patients experience cancer
induced bone pain (CIBP) (4). Unfortunately, scarce data is
available describing the severity of bone pain in patients with
lung cancer; only the incidence of bone pain or usage of
analgesics is reported (1–3, 5). In about one fifth of the
patients, Quality of Life (QoL) worsens after a diagnosis of
bone metastases (6). Furthermore, bone metastases are
associated with lower overall survival (OS) (6).
Tumor invasion into bone causes osteoclast and osteoblast
recruitment and modulation of genes and proteins involved in
the bone microenvironment. Numerous factors are involved in
the process of bone pain such as nociceptor activation and
sensitization, ectopic sprouting of nerve fibers and central
sensitization in the spinal cord and brain. Without treatment
of the underlying disease and/or local treatment, no bone healing
occurs in bone metastases, leading to a vicious circle of CIBP,
central sensitization resulting in more pain, and the development
of chronic bone pain (7). Therefore, early pain reduction
is important.
Due to the high incidence, chronic character, and negative
impact on QoL and OS, CIBP is an important issue that needs to
be addressed in metastatic NSCLC. According to the World
Health Organization (WHO) pain ladder, (bone) pain should
first be treated with paracetamol and/or non-steroidal anti-
inflammatory drugs (NSAIDs), followed if necessary by adding
mild, and later strong opioids (8). The extended use of NSAIDs
and opioids is associated with unwanted side effects (e.g., renal,
hepatic or gastro-intestinal) (7). Especially in the older
population (i.e., most patients with lung cancer), opioids can
lead to neurological complaints such as dizziness or cognitive
clouding, which in turn increases the likelihood of falling with
the risk of for example bone fractures (7). Furthermore, several
patients are reluctant to take opioids because of fear to become
addicted, or because of the side effects (9). Radiotherapy is
another effective treatment strategy for bone pain with a
complete pain resolution in approximately 50% of the patients
(10). Drawbacks of radiotherapy as treatment option are the time
delay, as it takes up to 6 weeks before a maximum treatment
effect is obtained (although ≥50% of responders have benefit
within 1–2 weeks) and a frequently occurring pain flare-up in the
first week after radiotherapy (10, 11). In addition, radiotherapy is
only feasible in patients with a limited number of painful
bone metastases.
The European Society for Medical Oncology (ESMO)
guideline on metastatic NSCLC (2018) recommends denosumab
or zoledronic acid in patients with NSCLC and bone metastases
considered at high risk for skeletal related events (SREs) and with
a life expectancy of >3 months (level of evidence I, grade of
recommendation B) (12). This recommendation is based on the
observation that bone targeted agents reduce SREs. Of note, pain
scores are not included in the definition of SRE, although necessity
for radiation because of painful bone metastases is included. For
denosumab it was found that in patients with bone metastases andFrontiers in Oncology | www.frontiersin.org 2no/mild baseline CIBP, time to pain interference with daily life
was longer compared with zoledronic acid. The ESMO advice is
based on randomized phase III trials that included solid tumors
(approximately 50% NSCLC) and early pain relief was not a
primary objective of these trials (12). Trials including patients
with bone metastases from prostate- or breast- or lung cancer
(N=607 of which 1 NSCLC), which evaluated the effect of
ibandronate (intravenous or oral) on bone pain showed pain
relief within seven days after start of ibandronate (13–15).
However, most of the patients received concomitant antineoplastic
treatment, therefore a pain relief effect of the systemic anti-cancer
therapy cannot be excluded and is it difficult to evaluate the
therapeutic effect on CIBP of bisphosphonate therapy alone.
The ESMO guideline on bone health in patients with cancer
(2020) states that multidisciplinary management (e.g., systemic
treatments, radiation therapy, surgery and supportive care) is
needed for effective treatment of metastatic bone disease. They
suggest radiotherapy as treatment of choice in localized CIBP,
but no specific treatment recommendations are made for
diffuse CIBP (10). The National Comprehensive Cancer
Network (NCCN) guideline on NSCLC and National Institute
for Health and Care Excellence (NICE) flowcharts on lung
cancer mention radiotherapy as pain relief option in CIBP
(16, 17).
Survival is improving in patients with NSCLC, partly because
of the survival benefit seen with immune checkpoint inhibitors
for a large proportion of patients and partly due to the
availability of tyrosine kinase inhibitors for the group of
patients with an oncogenic driver. As it is possible that these
patients live longer with CIBP, effective, preferably early pain
reducing treatments might be more relevant. We performed a
systematic review specifically focusing on early non-radiation
based pain relief options for NSCLC patients with CIBP.MATERIALS AND METHODS
Search Strategy and Selection Criteria
A systematic search of the literature published between January
1994 and June 2020 was performed using the PubMed, the
Cochrane Library and the ClinicalTrials.gov database.
Published studies were identified using a search strategy based
on the Patient-Intervention-Control-Outcome (PICO) method
(shown in Table 1 in the Supplementary Material) (18).
PRISMA 2009 checklist for systematic reviews is shown in
Table 3 in the Supplemental Material. Our clinical question
was to assess the efficacy of CIBP relief treatment options in
patients with NSCLC. Initially, we defined early pain relief as
pain reduction within two weeks. As we identified only one
trial, and to be as inclusive as possible, we expanded the time to
six weeks because in this period the maximum effect of
radiotherapy occurs. We excluded radiotherapy because of the
aforementioned drawbacks, and radioisotopes since the possible
interaction with systemic treatment which is the mainstay of
treatment for the majority of patients with NSCLC (19).
The main inclusion criteria were 1) prospective trials focusingOctober 2020 | Volume 10 | Article 509297
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minimum of 10 patients with NSCLC and with at least one bone
metastasis. All inclusion criteria for this systematic review are
summarized in Table 2 in the Supplementary Material.Study Selection
Two authors (AB and BB) independently screened the titles of
the selected studies and subsequently the abstracts of the eligible
studies. The same authors independently examined the full texts
of the selected articles regarding the inclusion criteria. Studies
were included if they met the eligibility criteria. To complete the
search, the references of all eligible articles were manually
searched for additional relevant articles. Also, the excluded
review articles were screened for relevant studies which were
not represented in the original search. The entire search and
selection were independently checked by a third reviewer (LH).
In case of disagreement during study inclusion, consensus
was sought.Data Selection
When available and applicable, the following data were extracted
from eligible studies by one author (AB) and independently by
another author (BB): year of publication, number of study arms,
randomization method, duration of study and follow-up,
histological diagnosis, intervention (i.e., type, dose, duration,
route and frequency), method of pain score (e.g., bone pain
inventory [BPI]), timing of pain score, efficacy of intervention on
pain relief, whether results were specifically for NSCLC or for all
included patients, and primary and secondary objectives of the
trials. Final approval of the extracted data was performed by LH.
The Jadad scale was used to assess the methodological quality
of the included trials (20). We did not perform a formal test of
heterogeneity because of the heterogeneous type of trials
included in the systemic review, with one third of the included
trials being single arm (i.e., per definition high risk of bias).RESULTS
Study Selection
The literature search identified 186 articles in total without
duplicates. As mentioned in the inclusion criteria, reviews were
excluded in the search strategy, but to broaden the search results
these reviews were manually searched for relevant studies. After
checking the reference list of the reviews identified with the
systematic search, 2 additional relevant articles were included. Of
these 188 articles, 151 were excluded because of non-relevant
titles. 18 of the 37 remaining articles were excluded because they
did not fulfill the inclusion criteria based on the abstract. After
screening of the full text of the remaining 19 articles, 14 articles
were excluded because of: no answer on the clinical question
(N = 4), radiotherapy as treatment modality (N = 1), radioisotopes
as treatment modality (N = 1), retrospective study or case report
(N = 2), and a language barrier (e.g., Chinese, Japanese or Serbian
language, N = 6). After manual search of the reference list ofFrontiers in Oncology | www.frontiersin.org 3included articles 5 other relevant articles were included. The
flowchart for article selection is shown in Figure 1.
Description of Studies
One phase II trial (21), six randomized controlled trials (22–27)
and three other prospective series (28–30) were included in this
review. The randomized controlled trials were double-blinded in
four trials (24–27) (of which one was placebo-controlled) and
open label in two (22, 23). Three studies were single-arm (21, 28,
29) six were 2-arm (22, 24–27, 30) and one 3-arm (23). In the
study of Zarogoulidis et al., the selection was made on
the presence of bone pain (30). The main characteristics of the
included studies are shown in Table 1. Four studies included
only patients with NSCLC, with a minimum of one bone
metastasis (21, 22, 28, 30). The other studies included also
patients with CIBP caused by bone metastases of solid
malignancies (256 out of 978 patients in total had NSCLC)
(23–27, 29). The number of patients with NSCLC enrolled in
the studies ranged from 14 (24, 28) to 144 (30), leading to in total
554 patients with NSCLC included in this review. Only in five
trials patients received pain modifying therapy alone (23–25, 27,
28), in all other trials, other anticancer treatment (mainly
chemotherapy) was given (21, 22, 26, 29, 30). The inclusion
criteria were quite similar across the included trials. The only
difference was the treatment history of the patients, e.g., pre-
treated with radiotherapy (28), chemonaïve (29) and presumably
chemonaïve (22, 30) and pre-treated with chemotherapy and/or
radiotherapy (21, 26). In the other trials, no information about
previous therapy is provided (23–27). The exclusion criteria
concerning comorbidities were comparable among eight
studies (21–27, 29). In two other studies, no exclusion criteria
were mentioned (28, 30).
The primary objectives of the included trials varied from
efficacy and safety of combined treatment of chemotherapy and
zoledronic acid (21, 29) effects of zoledronic acid on bone
resorption or formation markers (22), efficacy of treatment on
time to progression (TTP), OS (30), reduction in pain intensity
(24–27), frequency of breakthrough pain (24, 27), remission rate
(24), dose of morphine sulfate (24), and duration-adjusted
average change (DAAC) from baseline in the daily NRS worst
pain score (26). Six studies had (reduction in) pain score as
primary or secondary objective (23–28). Three studies assessed
bone pain or change in BPI from baseline as secondary objectives
(22, 29, 30). The study of Davidov et al. measured pain scores as
an exploratory objective (21). Table 1 provides a detailed
summary of all outcome variables of the included studies.
Results of Individual Studies
Method and Timing of Pain Score
The studies of Yoh et al. and Zarogoulidis et al. used the BPI as
method of measuring pain score (29, 30). In Zarogoulidis’s study,
the BPI was scored each clinical visit (the interval between study
visits was not further specified) (30), whereas in Yoh’s et al. study
this assessment was performed at baseline and after six weeks of
treatment (29). Three studies used the visual analogue scale
(VAS) expressed in figures or millimeters as method of
measuring pain score (23, 24, 27). The pain assessments tookOctober 2020 | Volume 10 | Article 509297
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weeks (23, 26, 27). Two other studies were not focused on a direct
pain score, they evaluated pain response indirectly with the use
of analgesics (21, 28). This was evaluated after one and three
cycles of chemotherapy (e.g., first measurement at three-four
weeks after start of anticancer treatment) (21) and within 48 h
after the intervention with a re-evaluation after two weeks (28).
One study used the McGill-Melzack pain score, which was
performed at baseline and after one and three months of
treatment (22). The numeric rating scale (NRS) as method of
measuring pain score was used by two trials (25, 26), one double
blind randomized trial only recorded till day three of treatment
(25), whereas the other recorded daily till day 35. Details on
methods and timing of pain score are in Table 2.
Efficacy of Treatment on Pain and Duration
of Response
Five studies (including 217 patients with NSCLC, out of 554
patients included in total) showed a significant treatment effect
on pain score (23–25, 27, 29). One double blind randomizedFrontiers in Oncology | www.frontiersin.org 4controlled trial, including 14 patients with NSCLC out of 113
included patients (10%) evaluating dexketoprofen trometamol
versus ketorolac showed superior of the former on pain rating
index (secondary outcome, p = 0.04) (24). One open label,
randomized controlled trial, showed that diclofenac combined
with celecoxib and morphine sulfate was superiority to NSAID
monotherapy combined with morphine sulfate in CIBP
reduction, measured with VAS (average VAS score at 28 days:
2.40 ± 1.20 vs 3.50 ± 0.70 (diclofenac monotherapy plus
morphine) or 3.40 ± 0.70 (celecoxib monotherapy plus
morphine), p = 0.006) (23). Another double blind randomized
controlled trial, including 75 patients with NSCLC out of 246
included patients (30%) showed an additional effect of the
combination of short acting oxycodone/paracetamol versus
placebo, added to standard long-acting opioids on reducing
bone pain (pain intensity difference (PID) after three days in
the placebo group 0.3, compared with 1.5 in the oxycodone/
paracetamol group, p<0.001) (25). One, double blind
randomized controlled, trial, including 19 patients with
NSCLC out of 100 included patients (19%), evaluating fentanylFIGURE 1 | Flowchart for article selection.October 2020 | Volume 10 | Article 509297
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tensity at d 7 +1 Pain intensity at d 3 ± 1, %
pts reaching PID ≥20mm
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d, day; Q, every; SRE, Skeletal Related Event; ORR, objective
HADS, Hospital Anxiety and Depression Scale; PGIC, Patient
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Study (year) Trial type Jadad
score
Total pts/
NSCLC
pts
Treatment arm Comparator arm Median
follow-up
(months)
P
Yousef and
Alzeftawy (27)
Phase NR, prospective
Randomized, 2 arms,
single center
4 19/100 Sublingual fentanyl% Piroxicam fast-dissolving
tablets%
1 Pain
frequ
onset
Liu et al. (23) Phase NR, prospective
Randomized 3 arms,
single center
3 95/342 Diclofenac + celecoxib +
morphine sulfate*
Diclofenac + morphine
sulfate*
Celecoxib + morphine sulfate*
NR VAS s
break
morp
Davidov (21) Phase NR, prospective
Single-arm, single center
0 53/53 Cycles of Gem (1,250 mg/m2)
on d1+8, CDDP (80 mg/m2) on
d1 and ZOL 4mg IV once Q3-4w
None NR
14 (mean)
Effica
Sjöland et al. (26) Phase NR, prospective
Randomized, double, 2
arms, multicenter
3 39/152 Flexible-dose pregabalin$ as
add-on to stable opioid analgesic
therapy
Placebo as add-on to stable
opioid analgesic therapy
NR DAAC
worst
dose
Sima et al. (25) Phase NR, prospective
Randomized
2 arms, multicenter
4 75/246 1–3 Oxycodone/paracetamol (5/
325 mg) Q6H d1-3# + morphine/
fentanyl patches
Placebo + morphine/
fentanyl patches
NR PID
Yoh et al. (29) Phase II Single-arm, single
center
0 35/35 1–4 cycles of CDDP (80 mg/m2),
D (60 mg/m2) and ZOL 4mg IV
on d1 Q3-4w
None 16 Feasi
ZOL
Francini et al. (22) Phase NR
Randomized 2 arms,
single center
2 55/55 ZOL 4 mg IV Q4w and CTX
(CDDP/GEM, CDDP/VBN,
CDDP/GEM + BEV)
IBA 50 mg q.d. and CTX
(CDDP/GEM, CDDP/VBN,
CDDP/GEM + BEV)
NR Effect
and B
Zarogoulidis et al.
(30)
Phase NR, prospective
Non-randomized, 2 arms,
single center
0 144/144 Pts with bone pain: ZOL 4mg IV
Q4w and 1–8 cycles of D (100
mg/m2), carbo (AUC = 6)
In case of response to CTX:
50Gy RTX to primary site
between 2-3rd cycle
Pts without bone pain: 1–8
cycles of D (100 mg/m2),
carbo (AUC = 6)
In case of response to CTX:
50Gy RT to primary site
between 2-3rd cycle
NR TTP,
Rodrıǵuez et al.
(24)
Phase NR, prospective
Randomized, 2 arms,
multicenter
4 14/113 Dexketoprofen trometamol 25
mg q.i.d.
Ketorolac 10 mg q.i.d. NR Pain
Gangi et al. (28) Phase NR
Observational, prospective
study, single center
0 14/25 Percutaneous injection of 3–25
ml ethanol 95%
None NR Pain
NR, not reported; BTP, break through pain; VAS, Visual Analogue scale; Tox, toxicity; Gem, gemcitabine; CDDP, cisplatin; D, docetaxel; ZOL, zoledronic acid; IV, intravenous;
response rate; OS, overall survival; NA, not applicable; DAAC, duration-adjusted average change; NRS, numeric rating scale; mBPI-sf, modified Brief Pain Inventory Short Form
Global Impression of Change; Q6H, every six hours; PID, pain intensity difference; w, week; CTX, chemotherapy; VBN, vinorelbine; BEV, bevacizumab; IBA, ibandronate; q.d., onc
bone-alkaline phosphatase; TTP, time to progression; Pts, patients; BM, bone metastasis; carbo, carboplatin; AUC, area under the curve; RT, radiotherapy; BPI, bone pain in
*Dosage of painkillers was as follows: diclofenac 100 mg/12h; celecoxib 400mg/day; morphine sulphate 10mg/12h, with a reduction of 50% or addition of 25% each time un
$Dosage of pregabalin was as follows: 100, 150, 300, or 600mg/day.
#The amount of placebo or oxycodone/paracetamol tablets was titrated step by step based on the pain assessment, up to 12 tablets per day maximum.
%Doses were adjusted individually. The effective dose was defined as the dose needed to control BTP (pain reduction by 50% in each pain episode without the occurrence or
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TABLE 2 | Overview of reported items on early bone pain relief.
e Efficacy treatment on pain Results speci-
fied for NSCLC
only
Duration
of
response
At 1 m
Fentanyl: 3.37 ± 0.74
Piroxicam: 3.47 ± 0.76
No NR
At d 282
Dicl+ Cele: 2.40 ± 1.20
Dicl: 3.50 ± 0.70
Cele: 3.40 ± 0.70
No NR
After 1 cycle: 5/53 pts reduced their analgesic need,
14/53 pts needed more pain medication, 34/53 pts
showed no change in pain medication
Yes NR
Mean change DAAC pregabalin: -1.53 (1.81)
Mean change DAAC (SD) placebo: -1.23 (1.74)
No NR
At d 3
PID placebo: 0.3
Oxycodone/
paracetamol: 1.5
No NR
mean BPI 1.0 ± 0.3 at 6 w (p<0.0001) Yes NR
89 “Trend for more rapid decrease in bone pain score in
favor of ZOL”
Yes NR
“no significant difference between treatment arms in
pain effect of ZOL compared to baseline”
Yes NR
At d 7
Dexketoprofen: 32 ± 24
Ketorolac: 40 ± 30
No NR
ment with
or CTX”
55% of pts score ≥3, 74% of pts score ≥2, 26% of
pts score11
No 10-27 w
rating scale; BPI, brief pain inventory; m, months; RTX, radiotherapy; CTX, chemotherapy.
t incomplete relief (75% reduction of analgesic requirement), score 2: good relief (25-50% reduction of analgesic
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Study (y) Method of pain score Timing of pain
score
Pain score on baseli
Yousef and Alzeftawy
(27)
VAS 3d, 1, 2, 3, 4 w Fentanyl: 8.09 ± 0.75
Piroxicam: 8.3 ± 0.75
Liu et al. (23) VAS 1st, 2nd, 4th w after
treatment
Dicl+ Cele: 8.48 ± 1.06
Dicl: 8.53 ± 1.06
Cele: 8.50 ± 1.06
Davidov (21) NR After 1 and 3 cycles NR
Sjöland et al. (26) NRS Each day NR
Sima et al. (25) NRS d 1–3 Placebo: 5.3
Oxycodone/
paracetamol: 5.2
Yoh et al. (29) BPI Baseline, after 6 w mean BPI 2.6 ± 0.2
Francini et al. (22) McGill-Melzack pain questionnaire Baseline, after 1
and 3 m
ZOL 1.98 ± 1.12, IBA 1.88 ± 0.
Zarogoulidis et al. (30) BPI Each clinical visit 78 pts ≤ 4, 8 pts 4 - 6, 1 pt > 8
Rodrıǵuez et al. (24) VAS in millimeters d 3 ± 1, d 7 + 1 Dexketoprofen: 69 ± 15
Ketorolac: 75 ± 16
Gangi et al. (28) Indirect measured by scale
according reduction of opiate
analgesics1
<48h after
intervention,
re-evaluation after
2w
“Pain relief insufficient after treat
opiate analgesics and RTX and/
VAS, Visual Analogue scale; w, weeks; Dicl, diclofenac; Cele, celecoxib; d, days; NR, not reported; pts, patients; NRS, numeric
1Scale consists of the following items: Score 4: complete relief (opiate analgesic drugs no longer necessary), score 3: very good bu
requirement), score 1: little of no relief (<25% reduction or no change of analgesic requirement).
2Gr 1: diclofenac and celecoxib, Gr 2: diclofenac, Gr 3: celecoxib.
3VAS scores at day 7 and 14 are shown in the original article, they showed superiority in pain reduction the diclofenac and celn
e
Brouns et al. Pain Relief in Bone Painversus piroxicam for CIBP reduction, reported for both drugs a
significant decrease in VAS score at 1 month. No significant
difference in efficacy was found between the treatment arms (27).
The only study with bisphosphonates, which found a significant
effect of treatment on pain score was the single-arm study of Yoh
et al. (29). They showed that treatment of both chemotherapy
and zoledronic acid reduced pain score at six weeks compared to
baseline. In another study, no significant difference in pain effect
of zoledronic acid between the treatment arms (docetaxel and
carboplatin +/- zoledronic acid) was observed (30). Another
double blind randomized controlled trial, including 39 patients
with NSCLC out of 152 included patients (26%), reported a non-
significant effect of pregabalin treatment on pain compared
placebo (DAAC from baseline in the daily NRS worst pain
score -1.53 vs. -1.23). The study of Francini et al. showed a
trend for more rapid decrease in bone pain score at one month in
favor of zoledronic acid compared to oral ibandronate (22).
Davidov et al. found only a reduced analgesic need in five out of
53 patients (10%), whereas most of the patients (34 out of 53
patients [64%]) had no change in pain medication after one
treatment cycle (21). One study showed a reduction of minimal
25%–50% of analgesic requirement in 74% of the patients and
55% of the patients had a reduction of 75% of analgesic
requirement after treatment with ethanol injections (28). The
duration of treatment response was only reported in one study
and was ten to 27 weeks (28).
Of note, none of the studies including patients with different
primary tumor histologies reported results for the subgroup of
patients with NSCLC. Table 2 provides an overview for reported
items on bone pain relief.
Discussion
CIBP is a clinically relevant problem in metastatic NSCLC due to
the high prevalence of bone metastases, the chronic character
and the negative impact on QoL and OS (6). Survival is
improving for NSCLC: five-year survival improved from 5% to
16%–31% for patients without targetable mutations, treated with
immune checkpoint inhibitors and five-year survival rates are
over 40% in patients with an EGFRmutation or ALK fusion (31–
37). It is possible that some of these patients survive a prolonged
time with CIBP that impairs QoL, making effective pain reducing
strategies necessary.
To obtain more insight in possible treatment options for early
pain relief in patients with NSCLC with bone metastases and
CIBP, we performed a systematic review on this topic excluding
radioisotopes and radiotherapy for the reasons mentioned above.
The initial scope of this review was early pain relief (pain relief
evaluated within two weeks of start of treatment), but this
resulted in limited number of eligible trials. To be more
inclusive, we broadened the time of “early pain relief” to a
maximum of six weeks. Even then, only ten studies were
eligible. Of note, the included trials were very heterogeneous
regarding treatments evaluated, primary endpoints, methods of
pain measurement and timing of assessment. Importantly, the
randomized trials included patients with different histologies,
and patients with NSCLC only comprised a subgroup in theseFrontiers in Oncology | www.frontiersin.org 7randomized trials (554 [44%] of included patients). Importantly,
not all treatments evaluated are comparable with recommended
pain treatment in clinical guidelines. For example, according to
international and national guidelines for breakthrough cancer
pain, shorting-acting morphine should be added to standard
dose long-acting morphine to treat breakthrough pain (38).
Three of the included studies indeed underscore the
importance of adding breakthrough medication to continuous
release medication (23, 25, 27). As the comparator arms of these
trials included a non-optimal treatment according to current
guidelines, the results found in these trials have limited value in
daily clinical practice. Another study excluded patients
previously or currently treated with a scheduled regimen of
painkillers, except acetaminophen and acetylsalicylic acid,
which is also not according to the WHO pain ladder (8, 24).
In most other studies (21, 22, 29, 30), systemic therapy and
pain relief therapy were administered concurrently, therefore
conclusions on the specific efficacy of pain relief therapy were
difficult as it cannot be excluded that the systemic therapy also
causes a reduction in pain. For zoledronic acid, only one study
showed an early pain reduction, but this pain reduction
disappeared at three months despite continuous bone targeted
agent use (22). While out of the scope of this review, information
on long-term pain reduction is also particularly important. Only
two studies provided follow-up of more than one year (21, 29).
As CIBP is a chronic problem, it is also of interest to know
information about the pain efficacy in the long term. However,
only the studies of Davidov and Yoh had a follow-up of more
than a year (21, 29). Duration of pain response and the
recurrence rate of CIBP was lacking.
What are other possible treatment options for CIBP in
NSCLC? The first step to achieve early pain relief in CIBP is
analgesics according the WHO pain ladder (8). This advice is
based on general pain management recommendations for
patients with cancer. As was found in this review, opioids are
indeed effective in the treatment of CIBP. Palliative radiotherapy
is frequently used in the treatment of CIBP, because of the high
response rate (around 85%). Drawbacks are the possibility of a
pain flare-up and the limited use in multiple painful bone
metastases (10). Besides that there are disparities in the access
to radiotherapy facilities in high and low-income countries. For
example, in Central Africa 0.05 machines are available per
million people versus 11.4 machines in North-America (39).
Furthermore, even if there is access, older, multi-fractionated
radiotherapy schedules for treatment of painful bone metastases
are often used, instead of the recommended single-fraction
radiotherapy, as was shown in a survey on radiation facilities
in African countries (40). This further limits the access to (up-to-
date) radiotherapy facilities and strengthens the need for other
early pain relief options for patients with NSCLC” .
Bisphosphonates and denosumab are also used to tread CIBP.
Trials including patients with breast and prostate cancer with
uncontrolled CIBP indeed showed a reduction in pain scores
with (loading doses) of bisphosphonates. However, data in
NSCLC is scarce and results found in our systematic review do
not show a clear reduction in CIBP in NSCLC. After our search,October 2020 | Volume 10 | Article 509297
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including patients with breast- or prostate cancer, loading doses
of ibandronate did not lead to rapid bone pain relief in patients
with NSCLC and uncontrolled bone pain (41). Denosumab was
compared with zoledronic acid in a randomized phase III trial
(1596 patients with solid tumors and at least one bone metastasis,
702 patients had NSCLC, patients with breast or prostate cancer
were excluded). Primary endpoint was time to first on-study
SRE, pain worsening was one of the other endpoints. Denosumab
significantly delayed the time to pain worsening (HR, 0.83; 95%
confidence interval, 0.71–0.97) in patients with no/mild baseline
pain, compared to zoledronic acid (42). Results regarding early
pain reduction in patients with baseline CIBP are not available.
Unfortunately, the recently published randomized phase III
Splendour trial, including only patients with advanced NSCLC
(inclusion irrespective of presence of bone metastases), did not
report data on the effect of denosumab on pain relief in the
subgroup of patients with painful bone metastases (43). The trial
design was to evaluate whether the addition of denosumab to
standard first-line treatment improved OS; the primary endpoint
was not met (12).
To the best of our knowledge, there is no explanation why for
example bisphosphonates showed a reduction of CIBP in some
malignancies but not in lung cancer (13–15, 41, 44, 45). Possible
explanations are; differences in tumor histology/biology or bone
metastasis metabolism [although bone turnover markers are
comparable between for example breast and lung cancer (46)],
which leads to different response on bone pain relief options, are
probably the most obvious. Also the usage of different
concomitant (systemic) therapies, which differs among
malignancies, could strengthen pain control (47). Therefore,
specific recommendations for (bone) pain relief are needed for
different malignancies and findings cannot be extrapolated.
Radioisotopes (e.g., samarium, strontium, and rhenium) are
an alternative treatment for CIBP. Radioisotopes have a rapid
onset of action, but data on NSCLC are limited and consist only
of subgroup analyses (19). Zoledronic acid combined with
radioisotopes is another treatment option. The efficacy of
adding a radioisotope (choice at discretion of investigator) to
zoledronic acid was evaluated in the randomized phase III RTOG
0517 trial (26/262 included patients had lung cancer). (48).
Primary endpoint was time to SRE development, pain control
was a secondary endpoint. Only patients with stable or no bone
pain were included. As a subgroup of patients did not have CIBP,
and one of the treatment arms consisted of radioisotopes, we
excluded this study in our article selection. The addition of
radioisotopes resulted in superior pain control at one month,
compared with zoledronic acid alone (median pain score of 0
versus 1, p=0.02). Subgroup analysis regarding the primary
tumor histology or the presence of baseline CIBP were not
performed (48). Because the relatively short duration of action
of radioisotopes, it is expected that this treatment must be
repeated several times if the patient has a prolonged survival.
Immune checkpoint inhibitors have become standard of care
treatment for most patients with advanced NSCLC and result in
durable responses in a subgroup of patients. For the subgroup ofFrontiers in Oncology | www.frontiersin.org 8patients with oncogenic drivers, tyrosine kinase inhibitors often
result in early and prolonged responses. For both classes of drugs,
effects onCIBPhavenot been specifically reported. It is possible that
in some patients, immune checkpoint inhibitors will not be very
active inpain reliefforCIBP, as Schmidet al. reported that efficacyof
immunotherapy depends on the metastatic location: the treatment
efficacy is less in bone lesions compared to lymph nodes (49).
However, CIBP related outcomes have not been reported.
Denosumab in combination with nivolumab, a programmed
death-1 (PD-1) inhibitor, is currently under evaluation in patients
withNSCLC and bonemetastases (NCT03669523) with the overall
response rate as primary outcome measurement. Time to first SRE
is one of the secondary outcome measurements but there is no
specific focus on pain relief. A phase II study with AL2846, a multi-
target tyrosine kinase receptor inhibitor versus zoledronic acid in
bone metastasized NSCLC (NCT04325776) is not yet recruiting.
The primary endpoint is time to first SRE, and effectiveness of
improving average daily pain (not specifically CIBP) is one of the
secondary outcomes. Another, not yet recruiting, phase IV, study is
zoledronic acid combined with radiotherapy for bonemetastasis of
NSCLC (NCT02480634). The primary outcome of this study is the
percentage of patients who reach objective bone pain response.
Experimental studies in animal models of CIBP have shown
alterations in, e.g., astrocytes or in the sphingolipid metabolism
in the spinal cord or showed the importance of connexins in the
cell-cell communication with probable effects on CIBP. Recently,
different studies focused on therapeutic options to block or alter
these pathophysiological changes. Blockade of interleukine-6
signaling is promising as it could lead to prevention or delay of
bone remodeling as well as decreased pain intensity (4).
Some possible drawbacks for this systematic review exist. A
point for discussion could be the chosen definition of early pain
reduction (pain reduction within six weeks). We chose this upper
limit to be as inclusive as possible to include treatment options
that resulted in pain reduction within a relatively short term. Of
note, for pain reduction treatment options within a shorter time
frame (e.g., one or two weeks), even less data is available. As
discussed above, bisphosphonates have different activity on early
CIBP reduction in breast- and prostate cancer compared with
NSCLC, we did not broaden our inclusion criteria to include
other tumor types (13–15, 41).
Furthermore, as expected with over half of the included trials
being single arm and/or not blinded and as shown by the Jadad
score the methodological quality of most included trials is poor.
Last, we did not include a formal test of heterogeneity, as only
very heterogeneous trials met our inclusion criteria.
Conclusion
In conclusion, despite the frequent occurrence of CIBP
combined with the negative effects on QoL and OS, literature
on the optimal treatment of CIBP in NSCLC is lacking. Most of
the recommendations given in current guidelines are mainly
based on data obtained in other tumors such as breast and
prostate. Therefore, randomized trials evaluating treatment
options with early pain relief for CIBP are necessary in lung
cancer patients.October 2020 | Volume 10 | Article 509297
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